The global Orphan Drugs for Adults market was valued at US$ 55670 million in 2023 and is anticipated to reach US$ 106140 million by 2030, witnessing a CAGR of 9.6% during the forecast period 2024-2030.

Orphan Drugs for Adults Market

Orphan drugs for adults refer to medications that are specifically developed and approved for the treatment of rare diseases or conditions in adult populations. These drugs are designed to address medical needs in adult patients who have limited treatment options due to the rarity of their conditions.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Orphan Drugs for Adults, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Orphan Drugs for Adults.

Report Scope

The Orphan Drugs for Adults market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Orphan Drugs for Adults market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Orphan Drugs for Adults companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Orphan Drugs for Adults Market Report

Report Metric	Details
Report Name	Orphan Drugs for Adults Market
Accounted market size in 2023	US$ 55670 million
Forecasted market size in 2030	US$ 106140 million
CAGR	9.6%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Oncology Drugs Gastrointestinal Drugs Neurology Drugs Cardio-vascular Drugs Others
Segment by Application	Hospital Pharmacies Retail pharmacies Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Abbvie, Orpharma, Amgen, Recordati, Novartis, Celgene, Amryt Pharma, Johnson & Johnson, GSK, Bristol-Myers Squibb Company, Roche Holding, Sanofi, Takeda, Pfizer, Vertex Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Orphan Drugs for Adults companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Orphan Drugs for Adults Market growing?

Ans: The Orphan Drugs for Adults Market witnessing a CAGR of 9.6% during the forecast period 2024-2030.

What is the Orphan Drugs for Adults Market size in 2030?

Ans: The Orphan Drugs for Adults Market size in 2030 will be US$ 106140 million.

Who are the main players in the Orphan Drugs for Adults Market report?

Ans: The main players in the Orphan Drugs for Adults Market are Abbvie, Orpharma, Amgen, Recordati, Novartis, Celgene, Amryt Pharma, Johnson & Johnson, GSK, Bristol-Myers Squibb Company, Roche Holding, Sanofi, Takeda, Pfizer, Vertex Pharmaceuticals

What are the Application segmentation covered in the Orphan Drugs for Adults Market report?

Ans: The Applications covered in the Orphan Drugs for Adults Market report are Hospital Pharmacies, Retail pharmacies, Others

What are the Type segmentation covered in the Orphan Drugs for Adults Market report?

Ans: The Types covered in the Orphan Drugs for Adults Market report are Oncology Drugs, Gastrointestinal Drugs, Neurology Drugs, Cardio-vascular Drugs, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Orphan Drugs for Adults Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Oncology Drugs

1.2.3 Gastrointestinal Drugs

1.2.4 Neurology Drugs

1.2.5 Cardio-vascular Drugs

1.2.6 Others

1.3 Market by Application

1.3.1 Global Orphan Drugs for Adults Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital Pharmacies

1.3.3 Retail pharmacies

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Orphan Drugs for Adults Market Perspective (2019-2030)

2.2 Orphan Drugs for Adults Growth Trends by Region

2.2.1 Global Orphan Drugs for Adults Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Orphan Drugs for Adults Historic Market Size by Region (2019-2024)

2.2.3 Orphan Drugs for Adults Forecasted Market Size by Region (2025-2030)

2.3 Orphan Drugs for Adults Market Dynamics

2.3.1 Orphan Drugs for Adults Industry Trends

2.3.2 Orphan Drugs for Adults Market Drivers

2.3.3 Orphan Drugs for Adults Market Challenges

2.3.4 Orphan Drugs for Adults Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Orphan Drugs for Adults Players by Revenue

3.1.1 Global Top Orphan Drugs for Adults Players by Revenue (2019-2024)

3.1.2 Global Orphan Drugs for Adults Revenue Market Share by Players (2019-2024)

3.2 Global Orphan Drugs for Adults Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Orphan Drugs for Adults Revenue

3.4 Global Orphan Drugs for Adults Market Concentration Ratio

3.4.1 Global Orphan Drugs for Adults Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs for Adults Revenue in 2023

3.5 Orphan Drugs for Adults Key Players Head office and Area Served

3.6 Key Players Orphan Drugs for Adults Product Solution and Service

3.7 Date of Enter into Orphan Drugs for Adults Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Orphan Drugs for Adults Breakdown Data by Type

4.1 Global Orphan Drugs for Adults Historic Market Size by Type (2019-2024)

4.2 Global Orphan Drugs for Adults Forecasted Market Size by Type (2025-2030)

5 Orphan Drugs for Adults Breakdown Data by Application

5.1 Global Orphan Drugs for Adults Historic Market Size by Application (2019-2024)

5.2 Global Orphan Drugs for Adults Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Orphan Drugs for Adults Market Size (2019-2030)

6.2 North America Orphan Drugs for Adults Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Orphan Drugs for Adults Market Size by Country (2019-2024)

6.4 North America Orphan Drugs for Adults Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Orphan Drugs for Adults Market Size (2019-2030)

7.2 Europe Orphan Drugs for Adults Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Orphan Drugs for Adults Market Size by Country (2019-2024)

7.4 Europe Orphan Drugs for Adults Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Orphan Drugs for Adults Market Size (2019-2030)

8.2 Asia-Pacific Orphan Drugs for Adults Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2019-2024)

8.4 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Orphan Drugs for Adults Market Size (2019-2030)

9.2 Latin America Orphan Drugs for Adults Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Orphan Drugs for Adults Market Size by Country (2019-2024)

9.4 Latin America Orphan Drugs for Adults Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Orphan Drugs for Adults Market Size (2019-2030)

10.2 Middle East & Africa Orphan Drugs for Adults Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2019-2024)

10.4 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Abbvie

11.1.1 Abbvie Company Detail

11.1.2 Abbvie Business Overview

11.1.3 Abbvie Orphan Drugs for Adults Introduction

11.1.4 Abbvie Revenue in Orphan Drugs for Adults Business (2019-2024)

11.1.5 Abbvie Recent Development

11.2 Orpharma

11.2.1 Orpharma Company Detail

11.2.2 Orpharma Business Overview

11.2.3 Orpharma Orphan Drugs for Adults Introduction

11.2.4 Orpharma Revenue in Orphan Drugs for Adults Business (2019-2024)

11.2.5 Orpharma Recent Development

11.3 Amgen

11.3.1 Amgen Company Detail

11.3.2 Amgen Business Overview

11.3.3 Amgen Orphan Drugs for Adults Introduction

11.3.4 Amgen Revenue in Orphan Drugs for Adults Business (2019-2024)

11.3.5 Amgen Recent Development

11.4 Recordati

11.4.1 Recordati Company Detail

11.4.2 Recordati Business Overview

11.4.3 Recordati Orphan Drugs for Adults Introduction

11.4.4 Recordati Revenue in Orphan Drugs for Adults Business (2019-2024)

11.4.5 Recordati Recent Development

11.5 Novartis

11.5.1 Novartis Company Detail

11.5.2 Novartis Business Overview

11.5.3 Novartis Orphan Drugs for Adults Introduction

11.5.4 Novartis Revenue in Orphan Drugs for Adults Business (2019-2024)

11.5.5 Novartis Recent Development

11.6 Celgene

11.6.1 Celgene Company Detail

11.6.2 Celgene Business Overview

11.6.3 Celgene Orphan Drugs for Adults Introduction

11.6.4 Celgene Revenue in Orphan Drugs for Adults Business (2019-2024)

11.6.5 Celgene Recent Development

11.7 Amryt Pharma

11.7.1 Amryt Pharma Company Detail

11.7.2 Amryt Pharma Business Overview

11.7.3 Amryt Pharma Orphan Drugs for Adults Introduction

11.7.4 Amryt Pharma Revenue in Orphan Drugs for Adults Business (2019-2024)

11.7.5 Amryt Pharma Recent Development

11.8 Johnson & Johnson

11.8.1 Johnson & Johnson Company Detail

11.8.2 Johnson & Johnson Business Overview

11.8.3 Johnson & Johnson Orphan Drugs for Adults Introduction

11.8.4 Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2019-2024)

11.8.5 Johnson & Johnson Recent Development

11.9 GSK

11.9.1 GSK Company Detail

11.9.2 GSK Business Overview

11.9.3 GSK Orphan Drugs for Adults Introduction

11.9.4 GSK Revenue in Orphan Drugs for Adults Business (2019-2024)

11.9.5 GSK Recent Development

11.10 Bristol-Myers Squibb Company

11.10.1 Bristol-Myers Squibb Company Company Detail

11.10.2 Bristol-Myers Squibb Company Business Overview

11.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Introduction

11.10.4 Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2019-2024)

11.10.5 Bristol-Myers Squibb Company Recent Development

11.11 Roche Holding

11.11.1 Roche Holding Company Detail

11.11.2 Roche Holding Business Overview

11.11.3 Roche Holding Orphan Drugs for Adults Introduction

11.11.4 Roche Holding Revenue in Orphan Drugs for Adults Business (2019-2024)

11.11.5 Roche Holding Recent Development

11.12 Sanofi

11.12.1 Sanofi Company Detail

11.12.2 Sanofi Business Overview

11.12.3 Sanofi Orphan Drugs for Adults Introduction

11.12.4 Sanofi Revenue in Orphan Drugs for Adults Business (2019-2024)

11.12.5 Sanofi Recent Development

11.13 Takeda

11.13.1 Takeda Company Detail

11.13.2 Takeda Business Overview

11.13.3 Takeda Orphan Drugs for Adults Introduction

11.13.4 Takeda Revenue in Orphan Drugs for Adults Business (2019-2024)

11.13.5 Takeda Recent Development

11.14 Pfizer

11.14.1 Pfizer Company Detail

11.14.2 Pfizer Business Overview

11.14.3 Pfizer Orphan Drugs for Adults Introduction

11.14.4 Pfizer Revenue in Orphan Drugs for Adults Business (2019-2024)

11.14.5 Pfizer Recent Development

11.15 Vertex Pharmaceuticals

11.15.1 Vertex Pharmaceuticals Company Detail

11.15.2 Vertex Pharmaceuticals Business Overview

11.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Introduction

11.15.4 Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2019-2024)

11.15.5 Vertex Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Bristol Myers Squibb Company

Vertex Pharmaceuticals

Recordati

Amryt Pharma

List of Tables

Table 1. Global Orphan Drugs for Adults Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Oncology Drugs

Table 3. Key Players of Gastrointestinal Drugs

Table 4. Key Players of Neurology Drugs

Table 5. Key Players of Cardio-vascular Drugs

Table 6. Key Players of Others

Table 7. Global Orphan Drugs for Adults Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Orphan Drugs for Adults Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Orphan Drugs for Adults Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Orphan Drugs for Adults Market Share by Region (2019-2024)

Table 11. Global Orphan Drugs for Adults Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Orphan Drugs for Adults Market Share by Region (2025-2030)

Table 13. Orphan Drugs for Adults Market Trends

Table 14. Orphan Drugs for Adults Market Drivers

Table 15. Orphan Drugs for Adults Market Challenges

Table 16. Orphan Drugs for Adults Market Restraints

Table 17. Global Orphan Drugs for Adults Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Orphan Drugs for Adults Market Share by Players (2019-2024)

Table 19. Global Top Orphan Drugs for Adults Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs for Adults as of 2023)

Table 20. Ranking of Global Top Orphan Drugs for Adults Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Orphan Drugs for Adults Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Orphan Drugs for Adults Product Solution and Service

Table 24. Date of Enter into Orphan Drugs for Adults Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Orphan Drugs for Adults Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Orphan Drugs for Adults Revenue Market Share by Type (2019-2024)

Table 28. Global Orphan Drugs for Adults Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Orphan Drugs for Adults Revenue Market Share by Type (2025-2030)

Table 30. Global Orphan Drugs for Adults Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Orphan Drugs for Adults Revenue Market Share by Application (2019-2024)

Table 32. Global Orphan Drugs for Adults Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Orphan Drugs for Adults Revenue Market Share by Application (2025-2030)

Table 34. North America Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Orphan Drugs for Adults Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Orphan Drugs for Adults Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Orphan Drugs for Adults Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Orphan Drugs for Adults Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Orphan Drugs for Adults Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Orphan Drugs for Adults Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Orphan Drugs for Adults Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Orphan Drugs for Adults Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Orphan Drugs for Adults Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Orphan Drugs for Adults Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Orphan Drugs for Adults Market Size by Country (2025-2030) & (US$ Million)

Table 49. Abbvie Company Detail

Table 50. Abbvie Business Overview

Table 51. Abbvie Orphan Drugs for Adults Product

Table 52. Abbvie Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 53. Abbvie Recent Development

Table 54. Orpharma Company Detail

Table 55. Orpharma Business Overview

Table 56. Orpharma Orphan Drugs for Adults Product

Table 57. Orpharma Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 58. Orpharma Recent Development

Table 59. Amgen Company Detail

Table 60. Amgen Business Overview

Table 61. Amgen Orphan Drugs for Adults Product

Table 62. Amgen Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 63. Amgen Recent Development

Table 64. Recordati Company Detail

Table 65. Recordati Business Overview

Table 66. Recordati Orphan Drugs for Adults Product

Table 67. Recordati Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 68. Recordati Recent Development

Table 69. Novartis Company Detail

Table 70. Novartis Business Overview

Table 71. Novartis Orphan Drugs for Adults Product

Table 72. Novartis Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 73. Novartis Recent Development

Table 74. Celgene Company Detail

Table 75. Celgene Business Overview

Table 76. Celgene Orphan Drugs for Adults Product

Table 77. Celgene Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 78. Celgene Recent Development

Table 79. Amryt Pharma Company Detail

Table 80. Amryt Pharma Business Overview

Table 81. Amryt Pharma Orphan Drugs for Adults Product

Table 82. Amryt Pharma Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 83. Amryt Pharma Recent Development

Table 84. Johnson & Johnson Company Detail

Table 85. Johnson & Johnson Business Overview

Table 86. Johnson & Johnson Orphan Drugs for Adults Product

Table 87. Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 88. Johnson & Johnson Recent Development

Table 89. GSK Company Detail

Table 90. GSK Business Overview

Table 91. GSK Orphan Drugs for Adults Product

Table 92. GSK Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 93. GSK Recent Development

Table 94. Bristol-Myers Squibb Company Company Detail

Table 95. Bristol-Myers Squibb Company Business Overview

Table 96. Bristol-Myers Squibb Company Orphan Drugs for Adults Product

Table 97. Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 98. Bristol-Myers Squibb Company Recent Development

Table 99. Roche Holding Company Detail

Table 100. Roche Holding Business Overview

Table 101. Roche Holding Orphan Drugs for Adults Product

Table 102. Roche Holding Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 103. Roche Holding Recent Development

Table 104. Sanofi Company Detail

Table 105. Sanofi Business Overview

Table 106. Sanofi Orphan Drugs for Adults Product

Table 107. Sanofi Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 108. Sanofi Recent Development

Table 109. Takeda Company Detail

Table 110. Takeda Business Overview

Table 111. Takeda Orphan Drugs for Adults Product

Table 112. Takeda Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 113. Takeda Recent Development

Table 114. Pfizer Company Detail

Table 115. Pfizer Business Overview

Table 116. Pfizer Orphan Drugs for Adults Product

Table 117. Pfizer Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 118. Pfizer Recent Development

Table 119. Vertex Pharmaceuticals Company Detail

Table 120. Vertex Pharmaceuticals Business Overview

Table 121. Vertex Pharmaceuticals Orphan Drugs for Adults Product

Table 122. Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2019-2024) & (US$ Million)

Table 123. Vertex Pharmaceuticals Recent Development

Table 124. Research Programs/Design for This Report

Table 125. Key Data Information from Secondary Sources

Table 126. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Orphan Drugs for Adults Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Orphan Drugs for Adults Market Share by Type: 2023 VS 2030

Figure 3. Oncology Drugs Features

Figure 4. Gastrointestinal Drugs Features

Figure 5. Neurology Drugs Features

Figure 6. Cardio-vascular Drugs Features

Figure 7. Others Features

Figure 8. Global Orphan Drugs for Adults Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Orphan Drugs for Adults Market Share by Application: 2023 VS 2030

Figure 10. Hospital Pharmacies Case Studies

Figure 11. Retail pharmacies Case Studies

Figure 12. Others Case Studies

Figure 13. Orphan Drugs for Adults Report Years Considered

Figure 14. Global Orphan Drugs for Adults Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Orphan Drugs for Adults Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Orphan Drugs for Adults Market Share by Region: 2023 VS 2030

Figure 17. Global Orphan Drugs for Adults Market Share by Players in 2023

Figure 18. Global Top Orphan Drugs for Adults Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs for Adults as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Orphan Drugs for Adults Revenue in 2023

Figure 20. North America Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Orphan Drugs for Adults Market Share by Country (2019-2030)

Figure 22. United States Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Orphan Drugs for Adults Market Share by Country (2019-2030)

Figure 26. Germany Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Orphan Drugs for Adults Market Share by Region (2019-2030)

Figure 34. China Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Orphan Drugs for Adults Market Share by Country (2019-2030)

Figure 42. Mexico Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Orphan Drugs for Adults Market Share by Country (2019-2030)

Figure 46. Turkey Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Orphan Drugs for Adults Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Abbvie Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 49. Orpharma Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 50. Amgen Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 51. Recordati Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 52. Novartis Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 53. Celgene Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 54. Amryt Pharma Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 55. Johnson & Johnson Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 56. GSK Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 57. Bristol-Myers Squibb Company Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 58. Roche Holding Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 59. Sanofi Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 60. Takeda Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 61. Pfizer Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 62. Vertex Pharmaceuticals Revenue Growth Rate in Orphan Drugs for Adults Business (2019-2024)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions